Finance

Lists
4543:TYO
Terumo Corp
2 277,50 JP¥
+0,26%
(+6,00) 1D
29-сен., 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4543...
Open
2 296 JP¥
High
2 306 JP¥
Low
2 253 JP¥
Mkt. cap
3,37 трлн
Avg. vol.
4,73 млн
Volume
4,84 млн
Dividend
1,32%
Quarterly dividend
7 JP¥
Ex-dividend date
2026-ж., 29-сен.
P/E ratio
20,43
52-wk high
2 689 JP¥
52-wk low
1 900 JP¥
EPS
111 JP¥
Shares outstanding
370,59 млн
No. of employees
31 миң
Open
2 296 JP¥
High
2 306 JP¥
Low
2 253 JP¥
Mkt. cap
3,37 трлн
Avg. vol.
4,73 млн
Volume
4,84 млн
Dividend
1,32%
Quarterly dividend
7 JP¥
Ex-dividend date
2026-ж., 29-сен.
P/E ratio
20,43
52-wk high
2 689 JP¥
52-wk low
1 900 JP¥
EPS
111 JP¥
Shares outstanding
370,59 млн
No. of employees
31 миң
News stories
From web sources and news partners
Profile
Terumo Corporation was founded in 1921 as Red Line Thermometer Corporation by a group of medical scientists led by Dr. Kitasato Shibasaburō to produce medical thermometers in Japan. The company's first product was "Jintan Taionkei", the first Japanese-made thermometer available for sale, and it has since expanded into a medical devices manufacturer, producing medical disposables, cardiovascular systems and diabetes care products. In 1971, Terumo opened its first overseas office in the United States. Since then, the company has established subsidiaries in Europe, South America, China, India, Philippines, Vietnam, Thailand, Australia and México. The company later expanded its product range to include coronary stents and catheters, and acquired, among others, the cardiovascular specialty companies Vascutek and Microvention in 2002 and 2006 respectively. Wikipedia
About Terumo Corp
CEO-
Employees31,2 миң
Founded1921-ж., 17-сен.
HeadquartersShibuya, Tokyo, Япония
SectorMedical device
Last report
2026-ж., 7-авг.
Fiscal period
Q1 2027
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
311,81 млд / 299,25 млд
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
274,96 млд
296,63 млд
300,32 млд
311,81 млд
Cost of goods sold
127,97 млд
143,44 млд
149,06 млд
133,27 млд
Cost of revenue
127,97 млд
143,44 млд
149,06 млд
133,27 млд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
97,88 млд
105,26 млд
107,66 млд
109,70 млд
Operating expense
101,90 млд
109,31 млд
98,62 млд
89,06 млд
Total operating expenses
229,87 млд
252,74 млд
247,68 млд
222,33 млд
Operating income
45,10 млд
43,88 млд
52,64 млд
89,48 млд
Other non operating income
-1,00 млн
2,00 млн
-409,00 млн
-4,00 млн
EBT including unusual items
45,95 млд
45,38 млд
31,66 млд
90,32 млд
EBT excluding unusual items
45,95 млд
45,38 млд
52,86 млд
90,32 млд
Income tax expense
10,90 млд
12,72 млд
5,30 млд
19,89 млд
Effective tax rate
23,72%
28,04%
16,73%
22,03%
Other operating expenses
4,02 млд
4,05 млд
-9,05 млд
-20,64 млд
Net income
35,05 млд
32,65 млд
26,37 млд
70,43 млд
Net profit margin
12,75%
11,01%
8,78%
22,59%
Earnings per share
-
-
-
-
Interest and investment income
1,02 млд
2,21 млд
-
2,38 млд
Interest expense
-18,00 млн
-463,00 млн
-1,32 млд
-1,48 млд
Net interest expenses
1,00 млд
1,75 млд
-1,32 млд
905,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
66,76 млд
69,98 млд
79,07 млд
116,67 млд
Gain or loss from assets sale
4,72 млд
154,00 млн
188,00 млн
12,00 млн
AI content may include mistakes. Learn more
Google колдонмолору